Peptide News Digest

CagriSema REDEFINE 9 Results, CVS GLP-1 Break-Even Price, China Insures Mazdutide and Ecnoglutide

Lower CagriSema doses gave about 21% weight loss, CVS puts GLP-1 break-even below $350 a month, and China adds two GLP-1s to its insurance list.

12 stories · Covering clinical-trials, research, industry, regulatory

Editor's Note

ObesityWeek opened in Washington on November 14 with data that look past the headline weight-loss number. Novo showed that lower CagriSema doses still produced about 21% weight loss, Lilly reported retatrutide's effect on sleep apnea and Zepbound's results in teenagers, and a Cleveland Clinic study found that what patients do after their first GLP-1 shapes their weight two years later. Price decides how far any of this reaches. CVS says employers would break even below $350 a month, China will reimburse two more GLP-1s for diabetes from January, and Mounjaro is now India's top-selling drug brand. In the U.S., two pharmacy groups used the last day of HHS's comment period to argue that the six-peptide compounding policy needs a verified ingredient supply before it can work. Antimicrobial peptides turned up in Singapore vet clinics, an AI design contest, and a fruit-fly study tying them to sleep.

Novo's REDEFINE 9: Lower CagriSema Doses Produced About 21% Weight Loss at 68 Weeks in Phase 3

In 309 adults with obesity or overweight and no diabetes, CagriSema 1.7 mg/1.7 mg and 1.0 mg/1.0 mg led to 20.7% and 21.0% average weight loss at 68 weeks if everyone stayed on treatment, versus 2.0% on placebo, Novo Nordisk said at ObesityWeek. Counting everyone regardless of adherence, losses were 19.4% and 18.6% versus 4.6%. The trial was not powered to compare the two doses. Results appeared in The Lancet Diabetes & Endocrinology, and an FDA decision on the 2.4 mg/2.4 mg dose is expected this quarter.

Lilly at ObesityWeek: Retatrutide Cut Sleep Apnea Events by Up to 60.6%, and Zepbound Lowered Teens' BMI 21.4%

In TRIUMPH-1, retatrutide reduced the apnea-hypopnea index by up to an average of 36.1 events per hour (60.6%) at 80 weeks in adults with moderate-to-severe obstructive sleep apnea and obesity or overweight. In TRIUMPH-2, which enrolled people who also had type 2 diabetes, the reduction was up to 28.4 events per hour (48.1%). In the Phase 3 SURMOUNT-ADOLESCENTS trial, Zepbound lowered BMI by an average of 21.4% at 72 weeks in 12- to 17-year-olds with obesity, and more than half no longer met the BMI criteria for obesity. Lilly presents the full results on November 15.

Novo's Ro Telehealth Studies: Food Noise Scores Fell Within a Month on Wegovy Injections and About 25% in Three Months on the Pill

In SIGNAL, 26,213 adults starting Wegovy injections through the Ro telehealth platform reported lower scores on a seven-item food noise questionnaire within the first month, a mean drop of 0.42 points from a baseline of 2.72. In OCTANE, 7,669 adults starting the Wegovy pill saw average scores fall from 2.8 to 2.1 over three months. Novo, which presented both retrospective analyses at ObesityWeek, noted that they rely on self-reported data and cannot show cause and effect.

Cleveland Clinic Study of 20,486 Patients: Switching Between Semaglutide and Tirzepatide Beat Stopping for Two-Year Weight Loss

Researchers led by Hamlet Gasoyan used health records of people who took semaglutide or tirzepatide for at least three months between 2021 and 2023 and compared what they did next. At two years, average weight loss was about 28% after bariatric surgery, 16% after switching between the two drugs, nearly 11% for those who stayed on their first drug, 8% on other obesity medicines, and 4% after stopping with no further treatment. Among people who started on tirzepatide, staying on it produced more weight loss than switching to semaglutide. The observational study appears in eClinicalMedicine.

CVS Health: Employers Would Break Even on GLP-1 Drugs Priced Below $350 a Month, Aetna Claims Show

Reuters reported that a CVS analysis of Aetna claims linked GLP-1 use to 10% to 12% fewer emergency room visits in the first and second years and, among about 4,000 people still on treatment after three years, 34% to 42% fewer hospitalizations. Over three years, plan sponsors saved $9,400 per person on medical bills but spent $13,300 more on prescriptions, a net cost of $3,900 at current prices. Chief medical officer Amy Compton-Phillips said drugmakers' direct-to-consumer prices, about $299 for Zepbound and $349 for Wegovy, suggest they could still profit below $350.

China Adds Pfizer's Ecnoglutide and Innovent's Mazdutide to Its National Insurance List for Type 2 Diabetes From January 1

China's National Healthcare Security Administration will cover the two GLP-1 drugs for patients with type 2 diabetes starting January 1, Reuters reported. They join Novo Nordisk's Ozempic, listed in 2022, and Lilly's Mounjaro and Innogen's efsubaglutide alfa, added this year. A listing usually widens access in exchange for lower prices. The update also includes a CAR-T cancer therapy from JW Therapeutics, the first CAR-T on the list.

Compounding Pharmacy Groups Back the HHS Peptide Policy but Want BPC-157 and Other Ingredients Bought Through U.S. Repackagers for a Year

In comments dated November 13, the Alliance for Pharmacy Compounding and the National Community Pharmacists Association supported HHS's pathway for 503A pharmacies to compound six peptides but questioned whether many ingredient makers can meet its testing specifications right away. They proposed that, for an initial year, pharmacies buy the peptide ingredients through FDA-registered U.S. repackagers or relabelers that verify each lot. They also asked what immunogenicity testing HHS expects and asked it to state that required reporting covers serious adverse events and quality problems sent to MedWatch, not routine dispensing data.

Singapore Start-Up Healbac Tests an Antimicrobial Peptide Cream for Pet Skin and Ear Infections at Six Vet Clinics

The Straits Times reported that Healbac, a spin-off from Singapore's A*STAR research agency, makes stem-cell-derived antimicrobial peptides, which its scientists found by growing human cells with bacteria and then modified chemically. First designed to replace food preservatives such as sodium nitrite, a topical cream is now being tested with six vet clinics as an option before antibiotics; its first patient, a French bulldog, saw a skin infection clear within three days. The company says it is still gathering clinical data before selling the product.

NeurIPS AMP Challenge Will Lab-Test Up to 500 AI-Designed Antimicrobial Peptides Against 20 Bacterial Strains

Organizers led by Ewa Szczurek of Helmholtz Munich, working with Cesar de la Fuente-Nunez's lab, described the competition in Genome Biology on November 14. Up to 20 teams that clear a computational round will each have 25 peptides made and tested in one laboratory against 20 Gram-positive and Gram-negative strains, eight of them multidrug-resistant, measuring both bacterial killing and damage to red blood cells. Published AI peptide designers are rarely validated the same way, and the contest aims to give the field a shared benchmark; its NeurIPS session is December 12.

WashU's PEP-CMV Peptide Vaccine Was Well Tolerated in Its First 36 Children and Young Adults With Aggressive Brain Tumors

In a Society for Neuro-Oncology abstract, Washington University researchers reported early safety data from a Phase 2 trial of PEP-CMV, a peptide vaccine aimed at the cytomegalovirus protein pp65, which these tumors carry but nearby normal brain does not. Thirty-six of a planned 106 patients aged 3 to 39 with recurrent medulloblastoma, newly diagnosed high-grade glioma, or diffuse intrinsic pontine glioma have received at least one dose. Grade 3 or 4 events possibly related to treatment included low blood counts, a seizure, and two cases of cytokine release syndrome. The authors called the vaccine well tolerated; efficacy results are not yet reported.

Fruit Flies Missing Certain Antimicrobial Peptides Slept Less, and Some Still Learned Normally

Ashoka University researchers report in PLOS Genetics that Drosophila mutants lacking various antimicrobial peptides slept less, took longer to fall asleep, and woke more easily. Flies missing the antifungal peptides Metchnikowin and Drosomycin slept the least yet learned and remembered normally, and knocking those genes down in glial cells reproduced the sleep loss. In Bomanin mutants, boosting sleep with drugs or behavioral methods improved learning and memory.